Thanks ZucchiniFlower. Pharam companies have no interest in Mucuna for obvious reasons nither the medical establishment, so we are left on our own with regard its use. The following link provides more information which I understand to mean that the anti PD benifits of mucuna may be due to costituents other than L-dopa. I will appreciate your comment

http://www.phcogrev.com/issue1/19.pdf
"Anti-Parkinson’s activity
Traditionally, M. pruriens has been used as a nerve tonic for
nervous system disorders. Because of the high concentration
of L-dopa in the seeds, it has been studied for its possible use
in Parkinson’s disease. Numerous in vivo studies also have
been conducted in rats and humans (28, 29). Hussain et al
proved that Mucuna pruriens is more effective than L-DOPA
in parkinson’s disease in animal model (30). Even L-Dopa free
fraction of seed showed significant antiparkinsonism activity
(31, 32). These studies state that at equivalent doses Mucuna
powder resembles L-DOPA with respect to modulation of
dopaminergic pathways, while the presence of other
constituents in contribute to improved antiparkinsonian
activity and greater tolerability in animals.
Clinical Research
HP-200, which is a first liquid levodopa contains Mucuna
pruriens endocarp, has been shown to be effective in the
treatment of Parkinson's disease. The long-term effect of
Mucuna pruriens endocarp in HP-200 on monoaminergic
neurotransmitters and its metabolite in various regions of the
rat brain was studied by Manyam et al. HP-200 at oral
administration of Mucuna pruriens endocarp in the form of
HP-200 had a significant effect on dopamine content in the
cortex with no significant effect on levodopa, norepinephrine
or dopamine, serotonin, and their metabolites- HVA, DOPAC
and 5-HIAA in the nigrostriatal tract. The failure of Mucuna
pruriens endocarp to significantly affect dopamine
metabolism in the striatonigral tract along with its ability to
improve Parkinsonian symptoms in the 6-hydorxydopamine
animal model and humans may suggest that its antiparkinson
effect may be due to components other than levodopa or that
it has an levodopa enhancing effect (33). In a clinical trail,
Eight Parkinson’s disease patients with a short duration Ldopa
response and on period dyskinesias completed a
randomised, controlled, double blind crossover trial. Mucuna
preparation led to a considerably faster onset of effect,
reflected in shorter latencies to peak L-dopa plasma
concentrations. Peak L-dopa plasma concentrations were 110
% higher and the area under the plasma concentration v time
curve (area under curve) was 165.3% larger. No significant
differences in dyskinesias or tolerability occurred (34).
Hypoglycaemic and Hypocholesterolemic activity
M.C. Pant et al reported that Mucuna pruriens possesses
hypoglycemic and hypocholesterolemic effects in the normal
rats (35). The sugar level was lowered by 39% and the
cholesterol level was lowered by 61% with the rats fed with
Mucuna pruriens.